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Abstract
Acute liver failure (ALF) and acute on chronic liver failure (AoCLF)
carry a high mortality. The rationale for extracorporeal systems is to
provide an environment facilitating recovery or a window of
opportunity for liver transplantation. Recent technologies have
used albumin as a scavenging molecule. Two different albumin
dialysis systems have been developed using this principle: MARS
(Molecular Adsorbent Recirculation System) and SPAD (Single-
Pass Albumin Dialysis). A third system, Prometheus (Fractionated
Plasma Separation and Adsorption), differs from the others in that
the patient’s albumin is separated across a membrane and then is
run over adsorptive columns. Although several trials have been
published (particularly with MARS), currently there is a lack of
controlled studies with homogenous patient populations. Many
studies have combined patients with ALF and AoCLF. Others have
included patients with different etiologies. Although MARS and
Prometheus have shown biochemical improvements in AoCLF and
ALF, additional studies are required to show conclusive benefit in
short- and long-term survival. The appropriate comparator is
standard medical therapy rather than head-to-head comparisons of
different forms of albumin dialysis.
Introduction
Acute liver failure (ALF) and acute on chronic liver failure
(AoCLF) have a high mortality. ALF is defined as development
of severe acute liver injury with impaired hepatic synthetic
function and encephalopathy in a patient without previous
liver disease [1]. AoCLF is defined as acute deterioration in
liver function over a 2- to 4-week period in a patient with pre-
existing chronic liver disease. In both conditions, the lack of
the metabolic and regulatory function of the liver results in
life-threatening complications that may include bleeding, renal
failure, hepatic encephalopathy (HE) or cerebral edema,
cardiovascular failure, and susceptibility to infections culmina-
ting in multi-organ failure [2].
Currently, the only effective therapy for patients with liver
failure is liver transplantation. Many patients die, however,
before a suitable graft is available, and for those who progress
to multi-organ failure, transplantation is not an option. The liver
often maintains some regenerative capacity, so the rationale
for supportive therapy and extracorporeal systems is to
provide an environment facilitating recovery to create or
prolong a window of opportunity for liver transplantation or, in
the best-case scenario, until native liver recovery occurs in
ALF or a period of stability for those with AoCLF [3].
In liver failure, a variety of ‘toxins’ accumulate as a result of
impaired hepatic function and clearance. Ammonia, inflam-
matory cytokines, aromatic amino acids, and endogenous
benzodiazepines have been implicated in the development of
HE and cerebral edema. Other systemic factors such as nitric
oxide and cytokines have been linked with circulatory and
renal dysfunction in liver failure. Pro-inflammatory cytokines
and oxidative stress have broad effects ranging from
increased capillary permeability to modulating cell-death and
immune dysregulation.
Various forms of dialysis were used in the treatment of liver
failure in the 1970s but failed to show benefit, possibly
because the majority of toxins in liver failure are water-
insoluble and albumin-bound and are poorly cleared by
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conventional hemodialysis or hemofiltration systems [4].
Charcoal hemoperfusion was similarly ineffective in a controlled
study, possibly in part due to biocompatibility issues [5].
Albumin administration has been shown to be beneficial in
spontaneous bacterial peritonitis and hepatorenal syndrome
(HRS) partly due to its ability to bind toxins [4]. Recent
artificial liver support technologies have used albumin as a
binding and scavenging molecule. Albumin dialysis involves
dialyzing blood against an albumin-containing solution across
a highly permeable high-flux membrane. The blood-bound
toxins are cleared by diffusion and taken up by the binding
sites of the albumin dialysate. Two different albumin dialysis
systems have been developed using this principle: MARS
(Molecular Adsorbent Recirculation System) and SPAD
(Single-Pass Albumin Dialysis). Prometheus (Fractionated
Plasma Separation and Adsorption, or FPSA) differs from the
others in that the patient’s plasma is separated across a
membrane and then is run over adsorptive columns. In this
review, we will examine the current evidence for the use of
these three technologies in patients with liver failure and its
complications.
Materials and methods
Relevant articles were found by electronic literature search
from the National Institutes of Health (PubMed) database as
well as bibliographies of recovered articles. We included full-
length articles written in English between 1999 and 2006.
Articles were excluded if statistical comparisons (p values)
were not provided versus baseline in uncontrolled studies or
versus the control group in randomized studies. In the
absence of randomized studies, our comments reflect a
narrative review of the available literature.
Results
I. Molecular Adsorbents Recirculation System
MARS was originally developed by Stange and colleagues
[6] (Teraklin AG, Rostock, Germany) in 1993. The system
consists of a blood circuit, an albumin circuit, and a classic
‘renal’ circuit. Blood is dialysed across an albumin-
impregnated high-flux dialysis membrane; 600 ml of 20%
human albumin in the albumin circuit acts as the dialysate.
Albumin-bound toxins in blood are released to the membrane.
These are subsequently picked up by albumin in the
dialysate, which then undergoes hemodialysis/hemofiltration
if required. The albumin dialysate is subsequently cleansed
via passage across two sequential adsorbent columns
containing activated charcoal and anion exchange resin.
These columns remove most of the water-soluble and
albumin-bound toxins. Because of the pore size of the
membrane, substances with a molecular weight of more than
50 kDa, such as essential hormones and growth factors
bound to albumin, are not removed [7].
Although there is a large amount of uncontrolled data about
MARS use, only a few small controlled studies to date have
examined the utility and safety of MARS in patients with
complications of liver failure. Most have focused on
improvements in biochemical profile, HE, and HRS. The
benefit of MARS has been more clearly shown in patients
with AoCLF (Table 1).
Molecular Adsorbent Recirculation System and acute on
chronic liver failure
In 2000, Mitzner and colleagues [8] reported 13 patients with
AoCLF and type 1 HRS treated with MARS. Patients
received a mean of five treatments and did not receive vaso-
Table 1
Molecular Adsorbent Recirculation System in acute on chronic liver failure
Improvements
Study Number Controlled Biochemical CVS CNS Survival (30 days)a
Stange et al. [7] 13 No Yes N/A Yes 69%
Schmidt et al. [10] 8 No Yes Yes No 50%
Jalan et al. [37] 8 No Yes Yes Yes 50%
Di Campli et al. [38] 13 No Yes N/A Yes 38%
Mitzner et al. [8] 13 Yes Yes Yes No Yes (37.5% versus 0% at 7 days)
Heemann et al. [9] 23 Yes Yes Yes Yes Yes (90% versus 55%)
Sen et al. [11] 18 Yes Yesb No Yes No (45% in both)
Blei [16] 70 Yes N/A N/A Yes N/A
Laleman et al. [12] 18 Yes Yesc Yes N/A N/A
Biochemical improvements: statistically significant reduction in bilirubin, bile acids, creatinine, and ammonia. aPercentages indicate uncontrolled
survival data; btrend did not reach statistical significance; cbilirubin and bile acids only. CNS, improvement in hemodynamic parameters (mean
arterial pressure, heart rate, vasopressor requirements); CNS, decrease in hepatic encephalopathy grade (neurological improvement); N/A, not
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pressors nor were any transplanted. The authors showed a
37.5% absolute survival benefit at day 7 versus 0% in
controls. Significant decreases in creatinine and bilirubin
were also noted in the MARS group.
Subsequently, Heemann and colleagues [9] randomly
assigned 23 patients with AoCLF (19 were alcoholics) to
MARS or standard medical therapy [SMT] (including dialysis
if necessary). Inclusion criteria included bilirubin of greater
than 340 µmol/l, HE of greater than grade 2, and renal
dysfunction. Patients in the MARS group received up to 10
treatments in the first 2 weeks. At day 30, 11/12 patients in
the MARS group were still alive, compared to only 6/11 in the
control group (p < 0.05). There were also statistically
significant decreases in bilirubin (43%) and bile acids (29%) in
the MARS group but not in the control group. A statistically
significant increase in mean arterial pressure (MAP) (p < 0.05)
as well as reductions in creatinine and HE grade (p < 0.06)
were noted in the MARS group. Although improvements with
MARS were significant compared to baseline, it is difficult to
extrapolate these results beyond 30 days. This study was
predominantly composed of patients with alcoholic cirrhosis
with a superimposed acute injury related to either recent
drinking or infection. Therefore, these results may not be appli-
cable to other populations with different etiologies of cirrhosis.
Molecular Adsorbent Recirculation System and
hemodynamics in acute on chronic liver failure
Although early uncontrolled studies have shown improvement
in MAP in patients with AoCLF on MARS, results have been
mixed in larger trials. In 2001, Schmidt and colleagues [10]
reported an uncontrolled study of eight patients with AoCLF
who received a single 10-hour MARS treatment. Statistically
significant increases over baseline in MAP and systemic
vascular resistance index (SVRI) (both p < 0.05) were noted.
However, Sen and colleagues [11] were unable to reproduce
these findings in their trial of 18 patients with alcohol-related
AoCLF randomly assigned to receive MARS or SMT
(including hemodialysis if indicated) over 7 days. This study
also assessed the effect of MARS on cytokine profiles and
nitric oxide, a potent vasodilator thought to have a significant
effect on systemic vascular resistance in liver failure.
Although HE improved significantly in the MARS group
compared to control (p < 0.05), there were no statistically
significant differences in cytokines, ammonia,
malondialdehyde (marker of oxidative stress), or nitric oxide
levels. There also was no statistically significant difference in
MAP noted in either group from baseline nor mortality benefit
at 30 days (4/9 alive in each group). The study of Schmidt
and colleagues [10] assessed hemodynamics after one run
on MARS, whereas the results of Sen and colleagues [11]
were obtained after multiple MARS treatments.
Interestingly, a more recent study of 18 patients with AoCLF
(alcoholic hepatitis) compared the hemodynamic effects of
MARS versus Prometheus versus SMT (six patients in each
arm; see next section) [12]. They showed statistically
significant increases in MAP and SVRI and a decrease in
endogenous vasoactive compounds with MARS compared to
Prometheus and SMT. Clearly, larger randomized controlled
trials are needed to resolve this issue.
Molecular Adsorbent Recirculation System and cerebral blood
flow in acute on chronic liver failure
Raised intracranial pressure is a cause of death in patients
with ALF. Although cerebral edema is rare in AoCLF, HE may
result in significant morbidity with loss of airway protection,
respiratory sepsis, and malnutrition. Accordingly, Schmidt
and colleagues [13] assessed the effect of MARS on
cerebral blood flow (CBF) in eight patients with AoCLF. Each
patient received a single 10-hour MARS treatment. CBF was
assessed by middle cerebral artery transcranial doppler
imaging alone. This commonly used methodology has been
previously validated using technecium-99 single-photon
emission computed tomography in concert (not used in this
study) [14]. In this cohort, CBF increased from baseline
(mean velocity of 42 to 72 cm/s; p < 0.05). Clinically, the
grade of clinical HE improved in three patients and remained
unchanged in the other five. Significant decreases in bilirubin
and arterial ammonia were also noted (p < 0.05). These
results may reflect the ability of MARS to decrease intra-
cerebral glutamine via reductions in ammonia [15]; however,
studies to date have not assessed the effects of serial MARS
treatments on CBF at more distant time endpoints.
MARS has demonstrated consistent benefit in HE in patients
with AoCLF. Blei [16] randomly assigned 70 patients with
grade 3 or 4 HE to MARS (n = 39) and SMT (n = 31). The
need for ventilation and the use of sedation were equal in
both groups. Patients in the MARS group received therapy
for 6 hours daily for 5 days or until a 2-grade improvement in
HE was achieved. At day 5, 72% of patients on MARS had
achieved a 2-grade improvement in HE versus 45% in the
SMT group (p = 0.017).
Molecular Adsorbent Recirculation System and acute liver
failure
There are limited controlled data examining the effect of
MARS in ALF (Table 2). In 2003, Schmidt and colleagues
[17] conducted a study to assess the effects of a single 6-
hour MARS treatment on hemodynamics, oxygen consump-
tion, and biochemical profile in patients with ALF (HE grade
3/4 developed within 7 days of symptoms). They randomly
assigned 13 patients with ALF due to acetaminophen
(n = 10), hepatitis B virus (HBV) (n = 2), and disulfram
(n = 1). Eight received MARS therapy and five received SMT
with cooling to match hypothermia induced by MARS.
Oxygen consumption decreased by 22% (p < 0.05) in the
MARS group, whereas there was no significant change in the
control group. SVRI increased by 46% in the MARS group
during the 6-hour run treatment versus a 6% increase in the
controls (p < 0.0001). MAP also increased in the MARS
Available online http://ccforum.com/content/11/3/215group (p < 0.001), whereas pressure was unchanged in
controls. Compared to baseline, there were significant reduc-
tions in bilirubin, creatinine, and urea (p < 0.05) but not in
ammonia in the MARS group. Survival was no different
between the MARS and control patients.
Other studies have shown biochemical improvements with
MARS in ALF without significant mortality benefit. In a
controlled study of 27 patients treated for ALF due to cardio-
genic shock, El Banayosy and colleagues [18] demonstrated
non-significant reductions in conjugated and total bilirubin
and mortality (Table 2). However, it is unclear whether this
population truly met criteria for ALF, as there is no mention of
grade of HE. In a case series of 10 patients with ALF due to
HBV, Tsai and colleagues [19] demonstrated biochemical
reductions (Table 2) at 3 months but mortality was 70% with
one patient receiving a liver transplant. Lee and colleagues
[20] have reported similar outcomes with MARS in a series of
13 patients with drug-induced ALF: a statistically significant
reduction in total bilirubin after a single MARS treatment
(p < 0.006) but an overall mortality of 85% at 20 days.
Molecular Adsorbent Recirculation System and
hemodynamics in acute liver failure
Lai and colleagues [21] reported 10 consecutive patients
(paracetamol 8, non-A non-B hepatitis 1, and isoniazid 1)
admitted with ALF and grade 3/4 HE who were treated with
MARS for 8 hours on 2 consecutive days. During the first
MARS treatment, there were significant increases in SVRI
(p = 0.02) and cardiac index (p = 0.01). However, these
changes were not maintained to the end of the second
MARS session. No significant changes in MAP or intracranial
pressure, as measured by reverse jugular bulb saturation,
were noted. Bilirubin levels were not significantly decreased
after MARS therapy. Three patients (30%) survived; all had
paracetamol hepatotoxicity and recovered without transplant.
Molecular Adsorbent Recirculation System and inflammatory
profile
It has been suggested that MARS has a beneficial effect in
patients with multi-organ dysfunction due to the inflammatory
milieu present in liver failure. Guo and colleagues [22]
reported an uncontrolled mixed cohort treated with MARS
(not shown in Tables 1 and 2); 11 patients had ALF and 13
had AoCLF. Entry requirements included evidence of two or
more of the following organ complications; HRS, HE (grade 2
or greater), disseminated intravascular coagulopathy, acute
respiratory distress syndrome, variceal bleeding, sepsis, and
cardiovascular failure. In total, the 24 patients received 66
treatments (6 to 24 hours per treatment) over the 7 days.
Their results showed a statistically significant decrease in
levels of nitric oxide, tumor necrosis factor-alpha (TNF-α),
interleukin (IL)-6, IL-8, and interferon-gamma (p < 0.01).
Significant improvements were also noted in level of
consciousness (Glasgow Coma Score of 7 to 13), renal
function, respiratory function, as well as increase in MAP
(p < 0.01 for all three comparisons). This study did not
differentiate between ALF and AoCLF in subsequent analysis.
The majority of patients had HBV (17/24).
Recently, Stadlbauer and colleagues [23] assessed cytokine
levels in eight patients with AoCLF of diverse etiologies
undergoing alternating treatments with MARS and Prometheus
in a random crossover design. Thirty-four treatments (17
MARS and 17 Prometheus) were available for analysis.
Although measurable plasma clearances were detected for
IL-6, IL-8, IL-10, and TNF-α, none was significant for MARS
or Prometheus. Based on these studies, MARS does not
Critical Care    Vol 11 No 3 Karvellas et al.
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Table 2
Molecular Adsorbent Recirculation System in acute liver failure
Improvements
Study Etiology Number Controlled Biochemical CVS CNS Survival (30 days)
Novelli et al. [39] Fulminant 9 No Yes N/A Yesa 66%
Isoniemi et al. [40] Toxic 26 No Yes N/A N/A 88%
Tsai et al. [19] Hepatitis B virus 10 No Yes Yes Yes 30%
Lee et al. [20] Drug (herb) 13 No Yes N/A No 15%
Lai et al. [21] Drug/Non-A non-B hepatitis 10 No No Yesb No 30%
Camus et al. [41] Mixed 23 No Yesc N/A Yes N/A
Schmidt et al. [17] Hepatitis B virus/Acetominophen 13 Yes Yesc Yes N/A No (62.5% versus 60%)
El Banayosi et al. [18] Ischemia 27 Yes Nod N/A N/A Yes (50% versus 32%)
Biochemical improvements: statistically significant reduction in bilirubin, bile acids, creatinine, and ammonia. aStatistics not provided; bstatistically
significant after first but not second MARS treatment; conly bilirubin and creatinine were statistically significant; dnon-significant improvement in
bilirubin. CNS, improvement in hemodynamic parameters (mean arterial pressure, heart rate, vasopressor requirements); CNS, decrease in hepatic
encephalopathy grade (neurological improvement); N/A, not assessed.appear to have a significant impact on the inflammatory
profile in AoCLF.
Molecular Adsorbent Recirculation System and bleeding
Blood coagulation is the result of a complex interaction
between procoagulant, anticoagulant, and fibrinolytic proteins,
many of which are synthesized by the liver. As previous liver
support/perfusion systems have been associated with
significant bleeding rates, two studies have studied coagula-
tion and bleeding with MARS. Faybik and colleagues [24]
described 33 patients undergoing 61 MARS treatments (15
with ALF, 8 with AoCLF, 3 with liver graft dysfunction, 5 with
sepsis, and 2 with cholestasis). Although there was a
statistically significant decrease in platelets and fibrinogen,
platelet function as measured by thromboelastography was
unaffected. Three moderate bleeding complications occurred
requiring transfusions (3 to 4 units of packed cells), but none
of the MARS runs had to be discontinued.
A second study by Doria and colleagues [25] examined 9
patients with cirrhosis who underwent MARS therapy: 6 with
AoCLF and 3 with intractable pruritis. Four patients deve-
loped bleeding while on MARS: 3 from gastrointestinal
sources and 1 from a genitourinary source. Four patients who
bled during MARS treatments subsequently died. MARS
resulted in a minor but statistically significant reduction in
platelet count (37 to 32 per millilitre; p < 0.05), worsened
platelet function by thromboelastography (p < 0.05), and an
increase in international normalised ratio for prothrombin time
(1.9 to 3.5; p = not significant).
Clearly, patients with all forms of liver failure are at high risk
for bleeding complications with or without MARS treatments.
Controlled trials are necessary before the magnitude of these
risks can be quantitated.
II. Prometheus: Fractionated Plasma Separation and
Adsorption
Prometheus (Fresenius AG, Hamburg, Germany), or FPSA,
was introduced in 1999. Its physiological basis is different
than MARS; patient plasma is fractionated through an
albumin-permeable filter with a cutoff of 250 kDa. Albumin
and other plasma proteins cross the membrane and pass
across two columns in series: one an anion-exchange column,
another a neutral resin adsorber. The cleansed albumin/
plasma is returned to the standard blood pool circuit where it
is then treated by conventional high-flux hemodialysis.
Early in vitro data showed that Prometheus effectively cleared
bilirubin, bile acids, and aromatic amino acids [26]. Important
compounds with a molecular weight of more than 250 kDa,
such as fibrinogen, were unchanged. A recent study showed
that in 18 patients with AoCLF (9 MARS and 9 Prometheus),
greater reduction ratios in total bilirubin, conjugated bilirubin,
and bile acids were obtained with Prometheus therapy than
with MARS treatments with identical duration of therapy
(5 hours), blood, and dialysate flow [27].
To date, no large controlled studies on Prometheus have
been published but some small case series have been
reported (Table 3). In 2003, Rifai and colleagues [28]
reported 11 patients with AoCLF, HE, and HRS who were
treated on 2 consecutive days (more than 4 hours) with
Prometheus. Statistically significant reductions in conjugated
and unconjugated bilirubin, bile acids, and ammonia levels
were noted. Despite the drop in ammonia levels, no clinical
change in HE was noted. Eight of 11 patients died, including
one due to variceal bleeding. Rifai and colleagues [29] have
also reported Prometheus use in 10 patients with HRS who
underwent two consecutive Prometheus treatments. Statis-
tically significant decreases in creatinine and urea levels and
improvement in arterial blood pH were observed. This is not
unexpected since conventional dialysis is incorporated into
the circuit. Significant decreases in serum-conjugated
bilirubin, bile acids, and ammonia levels were also noted. In
the same patient population (AoCLF), Rifai and colleagues
[30] have also shown that after two treatments, Prometheus
did not significantly alter inflammatory cytokine levels (C
reactive protein, IL-6, and TNF-α).
Prometheus has also been used as a bridge to liver
transplantation in patients with ALF. Skwarek and colleagues
Available online http://ccforum.com/content/11/3/215
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Table 3
Prometheus in liver failure
Improvements
Study Classification Number Controlled Biochemical CVS CNS Survival
Rifai et al. [28] Acute on chronic liver failure 11 No Yes No No 28% at 30 days
Skwarek et al. [31] Acute liver failure 13 No Yes N/A N/A 23% at 6 months
Laleman et al. [12] Acute on chronic liver failure (ethanol) 18 Yes Yesa No N/A N/A
Biochemical improvements: statistically significant reduction in bilirubin, bile acids, creatinine, and ammonia. aBilirubin and bile acids only. CNS,
improvement in hemodynamic parameters (mean arterial pressure, heart rate, vasopressor requirements); CNS, decrease in hepatic
encephalopathy grade (neurological improvement); N/A, not assessed.[31] reported 13 patients with ALF who received a total of 35
treatments lasting 6 to 10 hours. They noted statistically
significant decreases in total bilirubin and ammonia. Improve-
ments noted in acid-base balance and MAP did not reach
statistical significance. Seven patients were bridged to liver
transplantation, but only 3 were alive at 6 months. In summary,
Prometheus does not appear to improve mortality in ALF
unless transplant is performed, and even then, mortality is high.
The effect of Prometheus on systemic hemodynamics has not
yet been established. Laleman and colleagues [12] compared
the hemodynamic effects of Prometheus with MARS in 18
patients with AoCLF secondary to severe alcoholic hepatitis
(Maddrey score above 60). Six patients received MARS, 6
received Prometheus, and 6 received SMT (including hemo-
dialysis). After 3 consecutive days of therapy (mean approxi-
mately 6 hours), both MARS and Prometheus reduced serum
bilirubin (p < 0.005), and MARS increased MAP (∆ +9 mmHg;
p < 0.05) and SVRI (∆ +220 dyne-s/cm5 per m2; p < 0.05)
compared with Prometheus. No difference in hemodynamics
was noted between Prometheus and SMT. Levels of
endogenous norepinephrine, aldosterone, and vasopressin
were reduced (p < 0.05) in the MARS group, whereas there
was no statistically significant change in the Prometheus or
SMT arms.
III. Single-Pass Albumin Dialysis
SPAD differs from MARS and Prometheus in that it uses a
standard continuous venovenous hemodialysis (CVVHD) or
venovenous hemodiafiltration system without any additional
columns or circuits. Blood is dialysed against a standard
dialysis solution with the addition of 4.4% albumin in the
dialysate. The patient’s blood is dialysed through a high-flux
hollow-fibre hemodiafilter. In contrast to MARS, the albumin
dialysate is not regenerated as no adsorbent columns are
employed. A treatment is undertaken over 6 to 8 hours using
4.5 litres of dialysate and 700 ml of albumin.
Sauer and colleagues [32] published in vitro work in which
the efficiency of SPAD versus MARS versus standard CVVHD
was determined from plasma samples obtained from 18
patients by plasmapheresis. Ammonia, bile acids, and
conjugated bilirubin were added to the patient samples and
then clearance was determined. This study showed that the
removal of bile acids was similar between MARS and SPAD
and that SPAD removed significantly more conjugated
bilirubin than MARS (both significantly greater than CVVHD).
To date, little clinical data about SPAD have been published.
Seige and colleagues [33] reported that HE grade improved
in three patients with AoCLF and that one patient was
successfully transplanted and survived. Kreymann and
colleagues [34] reported that one patient with hyperacute
liver failure secondary to Wilson disease was successfully
bridged to transplantation and that SPAD efficiently cleared
copper and bilirubin. Currently, there have been no rando-
mized controlled studies showing its biochemical, hemo-
dynamic, or survival benefits in vivo.
Discussion
There continues to be great interest in and potential for the
various forms of extracorporeal albumin dialysis. However, at
present, we cannot make an evidence-based recommen-
dation supporting MARS, Prometheus, or SPAD. Of the
three, MARS is the best-studied albumin dialysis technology
in ALF and AoCLF; however, there is a paucity of robust
randomized studies, and most of the data are largely obser-
vational. Although studies in both ALF and AoCLF have
shown improvement (reduction) in biochemical markers (and
HE grade in AoCLF) on MARS, no conclusive mortality
benefit has been demonstrated to date, but studies are
currently in progress to address this issue. While promising,
hemodynamic improvement on MARS has not been
demonstrated in all studies. Based on two studies [24,25],
bleeding appears to be a significant potential issue with
MARS therapy. Clearly, larger randomized studies are
needed to definitively clarify issues of hemodynamics,
mortality benefit, and side effects.
Prometheus has also demonstrated improvements in
biochemical but not hemodynamic or inflammatory profiles.
Prometheus does appear to be safe and has not been shown
to increase bleeding complications in the limited uncontrolled
studies. No mortality benefit to date has been demonstrated.
A large, multi-centred randomized study in patients with
AoCLF is currently under way to clarify its benefits and side
effect profile. Given the paucity of data for SPAD, we cannot
comment on its risks and benefits.
There are many methodological limitations in the published
studies to date. First, many studies did not have homo-
geneous study groups (that is, ALF and AoCLF) or etiologies
(each often has very different prognoses). Several studies did
not stratify patients based on severity of illness (for example,
Child Pugh score and APACHE [Acute Physiology and
Chronic Health Evaluation] score) and hence it is difficult to
assess patient matching or the impact of underlying disease
on patient mortality with or without treatment. Duration and
number of treatments varied between studies, which may
explain inconsistent biochemical and hemodynamic findings.
Some studies did not clearly define adjuvant therapies in
either the albumin dialysis or SMT arms. Also, co-
interventions such as transfusion targets, ventilatory
strategies, hemodynamic targets, and algorithms for screening
and treatment of infectious diseases were often not explicitly
specified. Given this heterogeneity in previous studies, it is
difficult to develop evidence-based clinical (for example, HE
grade) and biochemical (for example, bilirubin) criteria to
define the need to initiate therapy and furthermore define the
optimal duration of therapy. These issues need to be
addressed in larger controlled studies in order to truly assess
the impact of albumin dialysis on mortality.
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extracorporeal liver support is patient selection. At present,
most patients being treated already have multi-organ failure
and have been found to have a poor prognosis irrespective of
MARS, Prometheus, or SPAD therapy (for example, many
studies report a 30-day mortality of greater than 70%). In
previous epidemiological studies, Jalan and colleagues [35]
have noted that patients with AoCLF with the presence of
organ failure (that is, Sequential Organ Failure Assessment
[SOFA] score above 8) have a distinctly worse prognosis
than decompensated cirrhosis patients without organ failure.
Furthermore, in these AoCLF patients with a SOFA score
above 8, those who previously decompensated in the
previous 6 months have a much worse prognosis (mortality at
1 year of 78% versus 34%) [35]. One could speculate that
selecting decompensated cirrhosis patients and ALF patients
prior to the development of multi-organ failure might prove to
be more beneficial.
At present, bilirubin is the most studied biochemical endpoint
of albumin dialysis therapy. However, since its decline does
not necessarily correlate with survival or other important
clinical endpoints such as bridging to liver transplant, other
surrogate markers are sorely needed. Inderbitzin and colleagues
[36] showed in post-surgical patients receiving MARS (either
partial hepatectomy for hepatocellular carcinoma or chol-
angiocarcinoma or early graft dysfunction) that the most
important prognostic markers for improvement on MARS
were an indocyanine green plasma disappearance rate of
above 5% and Factor V levels of above 30%. This again
suggests that earlier intervention will be most beneficial. This
is an area that needs further exploration.
Regardless of the form of liver support, patient prognosis is
universally poor if liver transplantation is not promptly
available. Although a statistically significant 30-day survival
benefit may be found, its clinical relevance, particularly in
patients with AoCLF in the absence of transplant, is doubtful.
Conclusion
In summary, these new techniques using albumin dialysis
represent potentially exciting advances in these desperately ill
patients with ALF and AoCLF. The challenge upon us now is
to learn how to best exploit these therapies to the patients’
advantage. We need to determine which biochemical and
clinical parameters correlate best with important patient
outcomes such as overall survival, bridging to liver trans-
plantation, and prevention of multi-organ failure. This
information will help determine which technical refinements
are most likely to be beneficial and can guide future clinical
studies. Different patient subgroups are likely to have
different benefits from albumin dialysis; trials should not
combine ALF and AoCFL, and different etiologies will have to
be evaluated separately. Adequately powered randomized
controlled trials are now required to show the benefit of
albumin dialysis. At this point, the appropriate comparator is
still SMT rather than head-to-head comparisons of different
forms of albumin dialysis in assessing short- and long-term
survival, need for liver transplantation, and prevention of multi-
organ failure.
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